insights_auto
Why is DRUG down 2.44%?
Dive Deeperchevron_right
DRUG:NASDAQ
Bright Minds Biosciences Inc
$52.69
arrow_downward
-2.44%(-1.32) 1D
Oct 13, 10:58:53 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DRUG...
Open
$54.01
High
$54.35
Low
$51.68
Mkt. cap
762.49M
Avg. vol.
115.80K
Volume
36.12K
52-wk high
$123.75
52-wk low
$47.23
Beta
-5.21
Shares outstanding
9.86M
No. of employees
26
Open
$54.01
High
$54.35
Low
$51.68
Mkt. cap
762.49M
Avg. vol.
115.80K
Volume
36.12K
52-wk high
$123.75
52-wk low
$47.23
Beta
-5.21
Shares outstanding
9.86M
No. of employees
26
News stories
From web sources and news partners
Stock Titan
·
59 minutes ago
Nasdaq files to remove Bone Biologics (Nasdaq: BBLG) warrants from listing and/or registration.
ChartMill
·
32 minutes ago
These S&P500 stocks are gapping in today's session
Bloomberg.com
·
28 minutes ago
S&P 500 Record Rally Meets Risk of Peaking Earnings Growth
CNBC
·
1 hour ago
Opening Bell: October 13 2026
Profile
Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use.
It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens.
The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York. Wikipedia
About Bright Minds Biosciences Inc